[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100543740":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":34,"responsibleParty":53,"collaborators":20,"id":55,"slug":20,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":58,"acronym":20,"eligibilityCriteria":59,"healthyVolunteers":60,"sex":61,"minAge":62,"maxAge":63,"enrollmentInfo":64,"targetDuration":20,"studyType":67,"phases":68,"briefSummary":70,"conditions":71,"keywords":20,"overallStatus":37,"whyStopped":20,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"Peking University Third Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Experimental arm","EXPERIMENTAL","Patients with TED will be recruited in the study.\n\nInterventions:\n\nDiagnostic Test: 18F-AlF-FAPI PET\u002FCT and 99mTc-DTPA SPECT\u002FCT.",[13],"Diagnostic Test: 18F-AlF-FAPI PET\u002FCT, 99mTc-DTPA SPECT\u002FCT",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DIAGNOSTIC_TEST","18F-AlF-FAPI PET\u002FCT, 99mTc-DTPA SPECT\u002FCT","Patients underwent 18F-AlF-FAPI PET\u002FCT and 99mTc-DTPA SPECT\u002FCT scans within 10 days.",[9],null,[22],{"name":23,"affiliation":5,"role":24},"Hui Li, Dr.","PRINCIPAL_INVESTIGATOR",[26,30],{"name":23,"role":27,"phone":28,"phoneExt":20,"email":29},"CONTACT","86-13121136769","huilee1990@163.com",{"name":31,"role":27,"phone":32,"phoneExt":20,"email":33},"Lingge Suo, Dr.","86-010-82264935","suolingge_1019@126.com",[35],{"facility":36,"status":37,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"Dept. of Nuclear Medicine, Peking University Third Hospital","RECRUITING","Beijing","Beijing Municipality","100191","China","CN",{"type":44,"coordinates":45},"Point",[46,47],116.39723,39.9075,{"lat":47,"lon":46},[50,51,52],{"name":23,"role":27,"phone":28,"phoneExt":20,"email":29},{"name":31,"role":27,"phone":32,"phoneExt":20,"email":33},{"name":23,"role":24,"phone":20,"phoneExt":20,"email":20},{"type":54,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100543740",false,"NCT06359795","Exploring the Value of 18F-AlF-FAPI PET\u002FCT in Assessing the Activity of Thyroid Eye Disease","Inclusion Criteria:\n\n1. Age ≥ 18 years;\n2. Patients diagnosed with TED;\n3. Complete understanding and voluntary participation in this study, with the signing of an informed consent form.\n\nExclusion Criteria:\n\n1. Severe liver or kidney dysfunction;\n2. Inability to maintain a supine position for 5 minutes to cooperate with the examination;\n3. Suffering from claustrophobia or other psychiatric disorders;\n4. Patients planning pregnancy or in the prenatal or lactation period;\n5. Other conditions deemed unsuitable for participation in the trial by the investigator.",true,"ALL","18 Years","80 Years",{"count":65,"type":66},50,"ESTIMATED","INTERVENTIONAL",[69],"NA","FAPI PET has been developed as a promising approach for the evaluation of fibroinflammatory, such as in inflammatory bowel disease. This prospective study aims to explore the value of 18F-AlF-FAPI PET\u002FCT in assessing the activity of Thyroid Eye Disease (TED) and investigate whether FAPI PET\u002FCT may be superior to 99mTc-DTPA SPECT\u002FCT for the diagnosis, therapy response assessment, and follow-up of TED.",[72],"Thyroid Eye Disease","2024-04-07",{"date":75,"type":76},"2024-04-11","ACTUAL",{"date":78,"type":76},"2023-12-15",{"date":80,"type":66},"2027-12-31",{"name":5,"class":6},1]